Related Experiment Video
Updated: Jul 6, 2026
Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
Published on: March 15, 2022
Guideline on antiplatelet and anticoagulation management in cardiac surgery
Joel Dunning1, Michel Versteegh, Alessandro Fabbri
1Department of Cardiothoracic Surgery, James Cook University Hospital, Middlesbrough, UK.
Insights
This guideline provides evidence-based recommendations for managing antiplatelet and anticoagulation therapy in cardiac surgery patients. It covers medication cessation, bleeding reduction strategies, and post-operative anticoagulation and thromboprophylaxis.
Area of Science:
- Cardiovascular Surgery
- Anesthesiology
- Hematology
Background:
- Managing antiplatelet and anticoagulation therapy is critical in cardiac surgery.
- Balancing bleeding risks and thromboembolic events is a significant clinical challenge.
Purpose of the Study:
- To provide evidence-based recommendations for antiplatelet and anticoagulation management in cardiac surgery.
- To guide clinicians on perioperative and postoperative strategies.
Main Methods:
- Review of evidence regarding aspirin, clopidogrel, and warfarin cessation.
- Evaluation of perioperative interventions for bleeding reduction (e.g., aprotinin, tranexamic acid).
- Assessment of anticoagulation post-valve replacement/repair and antiplatelet use for graft patency.
Main Results:
- Specific recommendations for the cessation of antiplatelet and anticoagulation agents prior to surgery.
- Guidance on utilizing agents like aprotinin and tranexamic acid to minimize bleeding.
- Evidence-based strategies for anticoagulation and antiplatelet therapy post-cardiac surgery.
Conclusions:
- Optimized antiplatelet and anticoagulation management is essential for patient outcomes in cardiac surgery.
- The guideline offers a framework for reducing complications and improving graft patency.
- Continuous review ensures recommendations remain current with emerging evidence.
Abstract:
This document presents a professional view of evidence-based recommendations around the issues of antiplatelet and anticoagulation management in cardiac surgery. It was prepared by the Audit and Guidelines Committee of the European Association for Cardio-Thoracic Surgery (EACTS). We review the following topics: evidence for aspirin, clopidogrel and warfarin cessation prior to cardiac surgery; perioperative interventions to reduce bleeding including the use of aprotinin and tranexamic acid; the use of thromboelastography to guide blood product usage; protamine reversal of heparin; the use of factor VIIa to control severe bleeding; anticoagulation after mechanical, tissue valve replacement and mitral valve repair; the use of antiplatelets and clopidogrel after cardiac surgery to improve graft patency and reduce thromboembolic complications and thromboprophylaxis in the postoperative period. This guideline is subject to continuous informal review, and when new evidence becomes available. The formal review date will be at 5 years from publication (September 2013).
Related Concept Videos
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:22Aneurysm IV: Nursing Management
01:28Cardiomyopathy VII: Pre and Post Operative Nursing Management
01:28Acute Coronary Syndrome IV: Interprofessional Care
01:26Cardiac Catheterization IV: Nursing Management
01:27Coronary Artery Disease V: Interprofessional Care